keyword
MENU ▼
Read by QxMD icon Read
search

cddp

keyword
https://www.readbyqxmd.com/read/27918099/mir-193b-mediates-cebpd-induced-cisplatin-sensitization-through-targeting-ets1-and-cyclin-d1-in-human-urothelial-carcinoma-cells
#1
Siao-Ren Lin, Hsin-Chih Yeh, Wei-Jan Wang, Hung-Lung Ke, Hui-Hui Lin, Wei-Chi Hsu, Shi-Yi Chao, Tzyh-Chyuan Hour, Wen-Jeng Wu, Yeong-Shiau Pu, A-Mei Huang
Transcription factor CCAAT/enhancer-binding protein delta (CEBPD) plays multiple roles in tumor progression. Studies have demonstrated that cisplatin (CDDP) induced CEBPD expression and had led to chemotherapeutic drug resistance. However, the underlying molecular mechanisms of CDDP-regulated CEBPD expression and its relevant roles in CDDP responses remain elusive. MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression in a sequence-specific manner. Abnormal miRNAs expression is associated with tumor progression...
December 5, 2016: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/27905409/compound-danshen-dripping-pills-modulate-the-perturbed-energy-metabolism-in-a-rat-model-of-acute-myocardial-ischemia
#2
Jiahua Guo, Yonghong Yong, Jiye Aa, Bei Cao, Runbin Sun, Xiaoyi Yu, Jingqiu Huang, Na Yang, Lulu Yan, Xinxin Li, Jing Cao, Nan Aa, Zhijian Yang, Xiangqing Kong, Liansheng Wang, Xuanxuan Zhu, Xiaohui Ma, Zhixin Guo, Shuiping Zhou, He Sun, Guangji Wang
The continuous administration of compound danshen dripping pills (CDDP) showed good efficacy in relieving myocardial ischemia clinically. To probe the underlying mechanism, metabolic features were evaluated in a rat model of acute myocardial ischemia induced by isoproterenol (ISO) and administrated with CDDP using a metabolomics platform. Our data revealed that the ISO-induced animal model showed obvious myocardial injury, decreased energy production, and a marked change in metabolomic patterns in plasma and heart tissue...
December 1, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27904042/risk-factors-associated-with-cisplatin-induced-nephrotoxicity-in-patients-with-advanced-lung-cancer
#3
Takanori Miyoshi, Nobuhiro Misumi, Mikako Hiraike, Yuki Mihara, Takashi Nishino, Minako Tsuruta, Yosei Kawamata, Yoichi Hiraki, Aki Kozono, Masao Ichiki
Cisplatin (CDDP) combination chemotherapy is widely administered to patients with advanced lung cancer. The dose depends on multiple factors, including whether the tumor is non-small-cell lung cancer (NSCLC) or small-cell lung cancer (SCLC). Although efficacy is limited by cisplatin-induced nephrotoxicity (CIN), little is known about the risk factors for this complication. The aim of this study was to identify the risk factors for CIN in patients with advanced lung cancer, both NSCLC and SCLC. We retrospectively reviewed clinical data for 148 patients who underwent initial chemotherapy including CDDP ≥50 mg/m(2) per patient per day for the first course at Kyushu Medical Center between October 2010 and September 2013...
2016: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/27900087/doublet-chemotherapy-with-cisplatin-and-pemetrexed-is-associated-with-a-favorable-outcome-in-patients-with-advanced-non-squamous-non-small-cell-lung-cancer-who-are-eligible-for-bevacizumab-and-maintenance-therapy
#4
Kazuhisa Nakashima, Haruyasu Murakami, Shota Omori, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Masahiro Endo, Toshiaki Takahashi
The previous AVAPERL trial demonstrated that induction therapy with first-line cisplatin (CDDP), pemetrexed (PEM) and bevacizumab (BEV), followed by continuation maintenance therapy with PEM+BEV, improved the progression-free survival (PFS) and overall survival (OS) compared with BEV alone (median PFS, 10.2 vs. 6.6 months and median OS, 19.8 vs. 15.9 months, respectively) in patients with advanced non-squamous non-small-cell lung cancer (non-Sq NSCLC). However, those findings were based on selected patients who were eligible for BEV and maintenance therapy...
November 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/27897082/ameliorative-effect-of-an-oxovanadium-iv-complex-against-oxidative-stress-and-nephrotoxicity-induced-by-cisplatin
#5
Abhishek Basu, Arin Bhattacharjee, Subhadip Hajra, Amalesh Samanta, Sudin Bhattacharya
OBJECTIVE: The present study was designed to investigate the chemoprotective efficacy of an L-cysteine-based oxovanadium (IV) complex, namely, oxovanadium (IV)-L-cysteine methyl ester complex (VC-IV) against cisplatin (CDDP)-induced renal injury in Swiss albino mice. METHODS: CDDP was administered intraperitoneally (5 mg/kg body weight) and VC-IV was administered orally (1 mg/kg body weight) in concomitant and 7 days pre-treatment schedule. RESULTS: CDDP-treated mice showed marked kidney damage and renal failure...
November 29, 2016: Redox Report: Communications in Free Radical Research
https://www.readbyqxmd.com/read/27890894/clinical-complete-response-from-chemotherapy-in-an-elderly-patient-with-metastatic-gastric-cancer-a-case-report
#6
Tetsuro Kawagoe, Yuta Maruki, Hiroyuki Nagoya, Yuki Kosugi, Teppei Akimoto, Hiroshi Yamawaki, Yasuhiro Kodaka, Mayumi Shimpuku, Nobue Ueki, Seiji Futagami, Kazumasa Miyake, Katsuhiko Iwakiri
An 81-year-old man was admitted with upper abdominal pain and weight loss. Esophagogastroduodenoscopy revealed a large tumor located from the gastric angle to the body. Histological analysis of a biopsy revealed a moderately differentiated adenocarcinoma. Computed tomography revealed metastases in the liver and lung and the patient was subsequently diagnosed with metastatic advanced gastric cancer. He was treated with chemotherapy using S-1 (80 mg/m(2)) and cisplatin (CDDP) (60 mg/m(2)). Twenty-two months after chemotherapy, the gastric tumor, and the nodules in the liver and lung, had disappeared...
2016: Journal of Nippon Medical School, Nippon Ika Daigaku Zasshi
https://www.readbyqxmd.com/read/27888498/chitosan-nanolayered-cisplatin-loaded-lipid-nanoparticles-for-enhanced-anticancer-efficacy-in-cervical-cancer
#7
Jing-Yi Wang, Yu Wang, Xia Meng
In this study, cisplatin (CDDP)-loaded chitosan-coated solid lipid nanoparticles (SLN) was successfully formulated to treat HeLa cervical carcinoma. The formulation nanoparticles were nanosized and exhibited a controlled release of drug in physiological conditions. The blank nanoparticles exhibited an excellent biocompatibility profile indicating its suitability for cancer targeting. The incorporation of CDDP in SLN remarkably increased the cancer cell death as evident from the MTT assay. Importantly, CDDP-loaded chitosan-coated SLN (CChSLN) significantly (P < 0...
December 2016: Nanoscale Research Letters
https://www.readbyqxmd.com/read/27885848/conveying-a-newly-designed-hydrophilic-anti-human-thymidylate-synthase-peptide-to-cisplatin-resistant-cancer-cells-are-ph-sensitive-liposomes-more-effective-than-conventional-ones
#8
Francesca Sacchetti, Domenico D'Arca, Filippo Genovese, Salvatore Pacifico, Eleonora Maretti, Miriam Hanuskova, Valentina Iannuccelli, Maria Paola Costi, Eliana Leo
Context LR-peptide, a novel hydrophilic peptide synthetized and characterized in previous work, is able to reduce the multi-drug resistance response in cisplatin (cDPP) resistant cancer cells by inhibiting human thymidylate synthase overexpressed in several tumors, including ovarian and colon-rectal cancers, but it is unable to enter the cells spontaneously. Objective The aim of this work was to design and characterize liposomal vesicles as drug delivery systems for the LR peptide, evaluating the possible benefits of the pH-responsive feature in improving intracellular delivery...
November 25, 2016: Drug Development and Industrial Pharmacy
https://www.readbyqxmd.com/read/27882231/organic-cation-transporter-6-directly-confers-resistance-to-anticancer-platinum-drugs
#9
Tetsuya Oguri, Eiji Kunii, Satoshi Fukuda, Kazuki Sone, Takehiro Uemura, Osamu Takakuwa, Yoshihiro Kanemitsu, Hirotsugu Ohkubo, Masaya Takemura, Ken Maeno, Yutaka Ito, Akio Niimi
Organic cation transporters (OCTs) of the solute carrier family 22 have a critical role in the cellular uptake of anticancer platinum drugs. Recently, we found that a decreased OCT6 expression is associated with a reduced intracellular uptake of cisplatin (CDDP), and concomitant resistance to CDDP. In the present study, we examined whether OCTs directly confer resistance to another platinum drug, oxaliplatin (L-OHP). To address this, we used parental lung cancer cell lines, PC-14 and SBC3; L-OHP-resistant sublines, PC-14/L-OHP and SBC3/L-OHP; and one CDDP-resistant subline PC-14/CDDP, to examine the relationships between the expression of OCTs and intracellular platinum drug concentration or platinum drug resistance...
November 2016: Biomedical Reports
https://www.readbyqxmd.com/read/27869279/highly-potent-extranuclear-targeted-luminescent-iridium-iii-antitumor-agents-containing-benzimidazole-based-ligands-with-a-handle-for-functionalization
#10
Jyoti Yellol, Sergio A Pérez, Gorakh Yellol, Juraj Zajac, Antonio Donaire, Gloria Vigueras, Vojtech Novohradsky, Christoph Janiak, Viktor Brabec, José Ruiz
A series of 6 substitutionally inert and luminescent iridium(iii) antitumor agents of the type [Ir(C(∧)N)2(N(∧)N)][PF6] containing a benzimidazole N(∧)N ligand with an ester group as a handle for further functionalization has been prepared. They exhibit IC50 values in the high nanomolar range in some ovarian and breast cancer cell lines (approximately 100× more cytotoxic than cisplatin (CDDP) in MDA-MB-231) and are located in the actin cortex predominantly as shown by confocal luminescence microscopy...
December 1, 2016: Chemical Communications: Chem Comm
https://www.readbyqxmd.com/read/27868436/an-oxovanadium-iv-complex-protects-murine-bone-marrow-cells-against-cisplatin-induced-myelotoxicity-and-dna-damage
#11
Abhishek Basu, Arin Bhattacharjee, Amalesh Samanta, Sudin Bhattacharya
Cisplatin (CDDP) is one of the first-line anticancer drugs that has gained widespread use against various forms of human malignancies. But, the therapeutic outcome of CDDP therapy is limited due to its adverse effects including myelotoxicity and DNA damage which may lead to the subsequent risk of developing secondary cancer. Hence, in search of a suitable cytoprotectant, this study investigated the probable protective efficacy of an oxovanadium(IV) complex, namely oxovanadium(IV)-L-cysteine methyl ester complex (VC-IV) against CDDP-induced myelosuppression and genotoxic damage in the bone marrow cells of Swiss albino mice...
November 20, 2016: Drug and Chemical Toxicology
https://www.readbyqxmd.com/read/27868285/review-of-chemotherapeutic-approaches-for-operable-and-inoperable-esophageal-squamous-cell-carcinoma
#12
REVIEW
Y Baba, H Saeki, Y Nakashima, E Oki, H Shigaki, N Yoshida, M Watanabe, Y Maehara, H Baba
The predominant histological types of esophageal cancer are adenocarcinoma and squamous cell carcinoma. Since these two histological types present as different diseases in terms of their epidemiology, pathologenesis, and tumor biology, separate therapeutic approaches should be developed against each type. While surgical resection remains the dominant therapeutic intervention for patients with operable esophageal squamous cell carcinoma (ESCC), their high rates of tumor recurrence have prompted investigation of multimodality therapies that combine surgery with chemotherapy, radiotherapy, and chemoradiotherapy...
November 21, 2016: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
https://www.readbyqxmd.com/read/27867537/aquaporin-3-facilitates-chemoresistance-in-gastric-cancer-cells-to-cisplatin-via-autophagy
#13
Xuqiang Dong, Yao Wang, Yangchun Zhou, Jianfei Wen, Shoulin Wang, Lizong Shen
Cisplatin (cDDP) remains one of the first-line chemotherapeutic agents for gastric cancer (GC) treatment, and resistance to cDDP is the major limitation in its clinical application. Mechanisms of cDDP resistance have been shown to be varied and complicated. Aquaporin 3 (AQP3) has been demonstrated to be overexpressed in GC tissues and is thought to be involved in GC carcinogenesis and progression. However, the role of AQP3 in chemosensitivity of GC to cytotoxic agents remains unknown. In this study, we show that AQP3 overexpression induced resistance to cDDP in AGS cells (P<0...
2016: Cell Death Discovery
https://www.readbyqxmd.com/read/27837525/a-case-report-of-curative-distal-gastrectomy-for-stage-iv-gastric-cancer-after-chemoradiotherapy-in-a-patient-with-a-gastrojejunal-gastric-bypass
#14
Masataka Shimonosono, Sumiya Ishigami, Takaaki Arigami, Yoshikazu Uenosono, Yasuto Uchikado, Yoshiaki Kita, Yuko Kijima, Hiroshi Kurahara, Yuko Mataki, Kosei Maemura, Shoji Natsugoe
BACKGROUND: Advanced gastric cancer in the lower third of the stomach often results in stricture of the gastric cavity and digestive symptoms. Gastrojejunostomy has been suggested to improve such symptoms, and the advent of new anticancer agents for gastric cancer has improved the response rate of the disease, which makes it possible to perform R0 gastrectomy in part of patients with stage IV gastric cancer. We experienced a rare case in which a patient with stage IV gastric cancer and cancerous pyloric stenosis was treated with R0 surgery after undergoing a gastrojejunal bypass procedure and multidisciplinary treatment...
December 2016: Surgical Case Reports
https://www.readbyqxmd.com/read/27824145/sulforaphane-improves-chemotherapy-efficacy-by-targeting-cancer-stem-cell-like-properties-via-the-mir-124-il-6r-stat3-axis
#15
Xingxing Wang, Yuan Li, Yi Dai, Qinqiang Liu, Shilong Ning, Jiao Liu, Zhaoxia Shen, Dongmei Zhu, Fei Jiang, Jianping Zhang, Zhong Li
Gastric carcinoma (GC) is the second leading cause of cancer-related mortality worldwide. The efficacy of standard chemotherapy for GC, such as cisplatin (CDDP), is dissatisfactory partly due to the toxic/side-effects. Sulforaphane (SFN), which exhibits effective anti-cancer functions, is a phytochemical converted from cruciferous plants. Our present study aimed to identify whether SFN could enhance the anti-cancer effects of low-dose CDDP and to determine the underlying mechanisms. Herein, co-exposure of SFN and CDDP significantly inhibited the viabilities of gastric cancer cells...
November 8, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27816686/in-vitro-and-in-vivo-synergistic-therapeutic-effect-of-cisplatin-with-human-papillomavirus16-e6-e7-crispr-cas9-on-cervical-cancer-cell-line
#16
Shuai Zhen, Jiao-Jiao Lu, Li-Jie Wang, Xiao-Min Sun, Jia-Qi Zhang, Xu Li, Wen-Juan Luo, Le Zhao
PURPOSE: Human papillomavirus (HPV) type 16 is one of the major etiologic factors of cervical cancer. Our study aims to investigate the potentiality of the antiviral clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system (CRISPR/Cas9) targeting the E6 and E7 oncogenes of HPV16 as a potential chemosensitizer of cisplatin (cis-diaminedichloroplatinum II; CDDP) for cervical cancer. METHODS: Specifically, the therapeutic efficacy of combination of CDDP and HPV16 E6 + E7-CRISPR/Cas9 was assessed in cervical cancer cells and cervical cancer xenograft models...
October 28, 2016: Translational Oncology
https://www.readbyqxmd.com/read/27793948/clinical-significance-of-the-histoculture-drug-response-assay-in-breast-cancer
#17
Yoshiaki Shinden, Yuko Kijima, Munetsugu Hirata, Hideo Arima, Akihiro Nakajyo, Kiyonori Tanoue, Kosei Maemura, Shoji Natsugoe
BACKGROUND/AIM: Despite the fact that breast cancer patients are generally administered systemic chemotherapy after surgical treatment, predictive factors that allow optimization of chemotherapy are needed. The histoculture drug response assay (HDRA) is a clinically practical in vitro drug-response assay for identifying optimal anticancer agents. PATIENTS AND METHODS: Thirty-eight primary breast cancer patients who underwent surgical treatment without receiving systemic neoadjuvant therapy were analyzed...
November 2016: Anticancer Research
https://www.readbyqxmd.com/read/27793927/anticancer-effects-of-a-new-aminosugar-conjugated-platinum-complex-agent-against-cisplatin-resistant-gastric-cancer
#18
Noriyuki Hayashi, Hiromi Kataoka, Shigenobu Yano, Jun-Ichi Kikuchi, Mamoru Tanaka, Hirotada Nishie, Yuma Kinoshita, Miki Hatano, Akihiro Nomoto, Akiya Ogawa, Masahiro Inoue, Tsutomu Mizoshita, Takaya Shimura, Yoshinori Mori, Eiji Kubota, Satoshi Tanida, Takashi Joh
BACKGROUND/AIM: Resistance against cisplatin is a problem for the success of gastric cancer chemotherapy. Herein, we evaluated the antitumor effect of a new aminosugar-conjugated, mono-functional platinum complex (Pt-Oqn), which forms a single covalent bond with DNA. MATERIALS AND METHODS: We compared the cytotoxicity of Pt-Oqn to that of cisplatin (CDDP), oxaliplatin (L-OHP) and carboplatin (CBDCA). We also compared Pt-Oqn and cisplatin for DNA double-strand breaks based on phosphorylated histone H2AX levels in cancer cells and antitumor effects in xenograft models...
November 2016: Anticancer Research
https://www.readbyqxmd.com/read/27790371/total-or-partial-vertebrectomy-for-lung-cancer-invading-the-spine
#19
Soichi Oka, Hiroki Matsumiya, Shuichi Shinohara, Taiji Kuwata, Masaru Takenaka, Yasuhiro Chikaishi, Ayako Hirai, Naoko Imanishi, Koji Kuroda, Sohsuke Yamada, Hidetaka Uramoto, Eiichiro Nakamura, Fumihiro Tanaka
BACKGROUND: Surgery for lung cancer invading the spine remains challenging associated with high morbidity and mortality. However, recent advances in surgical techniques as well as in perioperative care may improve outcomes of lung cancer surgery with vertebrectomy. We describe our surgical approach and assess the outcome lung cancer invading the spine. METHODS: We retrospectively reviewed our recent experiences of lung cancer with vertebral invasion, in which we have performed total or partial vertebrectomy from January 2011 through April 2015...
December 2016: Annals of Medicine and Surgery
https://www.readbyqxmd.com/read/27787693/intracellular-uptake-of-an-antitumor-active-azole-bridged-dinuclear-platinum-ii-complex-in-cisplatin-resistant-tumor-cells
#20
Shuichi Kishimoto, Megumi Yasuda, Ryosuke Suzuki, Shoji Fukushima
A cationic azolato-bridged dinuclear platinum(II) complex, [{cis-Pt(NH3)2}2(μ-OH)(μ-methyl-pyrazolate)](2+) (4M-PzPt), was developed to overcome resistance to cisplatin (CDDP). This study aimed to assess the cytotoxicity of 4M-PzPt against a CDDP-resistant cell line, H4-II-E/CDDP, and compare the intracellular accumulation of CDDP and 4M-PzPt. H4-II-E and H4-II-E/CDDP displayed similar sensitivity to 4M-PzPt; however, the sensitivity of H4-II-E/CDDP to CDDP was approximately 19-fold lower than that of H4-II-E...
December 2016: Biometals: An International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine
keyword
keyword
85891
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"